Zobrazeno 1 - 10
of 294
pro vyhledávání: '"Peyman Hadji"'
Autor:
Peter A. Fasching, Chunling Hu, Steven N. Hart, Matthias Ruebner, Eric C. Polley, Rohan D. Gnanaolivu, Andreas D. Hartkopf, Hanna Huebner, Wolfgang Janni, Peyman Hadji, Hans Tesch, Sabrina Uhrig, Johannes Ettl, Michael P. Lux, Diana Lüftner, Markus Wallwiener, Lena A. Wurmthaler, Chloë Goossens, Volkmar Müller, Matthias W. Beckmann, Alexander Hein, Daniel Anetsberger, Erik Belleville, Pauline Wimberger, Michael Untch, Arif B. Ekici, Hans-Christian Kolberg, Arndt Hartmann, Florin-Andrei Taran, Tanja N. Fehm, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss, Lothar Häberle, Fergus J. Couch
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-7 (2024)
Abstract Germline mutations in BRCA1 and BRCA2 (gBRCA1/2) are required for a PARP inhibitor therapy in patients with HER2-negative (HER2−) advanced breast cancer (aBC). However, little is known about the prognostic impact of gBRCA1/2 mutations in a
Externí odkaz:
https://doaj.org/article/7fc65e7d8ec9445caafcbb4945b9c522
Autor:
Andreas Schneeweiss, Johannes Ettl, Diana Lüftner, Matthias W. Beckmann, Erik Belleville, Peter A. Fasching, Tanja N. Fehm, Matthias Geberth, Lothar Häberle, Peyman Hadji, Andreas D. Hartkopf, Carsten Hielscher, Jens Huober, Eugen Ruckhäberle, Wolfgang Janni, Hans Christian Kolberg, Christian M. Kurbacher, Evelyn Klein, Michael P. Lux, Volkmar Müller, Naiba Nabieva, Friedrich Overkamp, Hans Tesch, Elena Laakmann, Florin-Andrei Taran, Julia Seitz, Christoph Thomssen, Michael Untch, Pauline Wimberger, Rachel Wuerstlein, Bernhard Volz, Diethelm Wallwiener, Markus Wallwiener, Sara Y. Brucker
Publikováno v:
Breast, Vol 54, Iss , Pp 88-95 (2020)
Purpose: Treatment with CDK4/6 inhibitors and endocrine therapy (CDK4/6i + ET) is a standard for patients with advanced hormone receptor–positive, HER2-negative (HR + HER2–) breast cancer (BC). However, real-world data on the implementation of th
Externí odkaz:
https://doaj.org/article/06b4953fd7094428a800955c7f592096
Autor:
Komal Waqas, Joana Lima Ferreira, Elena Tsourdi, Jean-Jacques Body, Peyman Hadji, M.C. Zillikens
Publikováno v:
Journal of Bone Oncology, Vol 28, Iss , Pp 100355- (2021)
Introduction: Adjuvant endocrine therapy induces bone loss and increases fracture risk in women with hormone-receptor positive, early-stage breast cancer (EBC). We aimed to update a previous position statement on the management of aromatase inhibitor
Externí odkaz:
https://doaj.org/article/803944591f2946a59120e3e4ca5c9b1c
Autor:
Markus Wallwiener, Naiba Nabieva, Manuel Feisst, Tanja Fehm, Johann de Waal, Mahdi Rezai, Bernd Baier, Gerold Baake, Hans-Christian Kolberg, Martin Guggenberger, Mathias Warm, Nadia Harbeck, Rachel Wuerstlein, Jörg-Uwe Deuker, Peter Dall, Barbara Richter, Grischa Wachsmann, Cosima Brucker, Jan Willem Siebers, Milos Popovic, Thomas Kuhn, Christopher Wolf, Hans-Walter Vollert, Georg-Peter Breitbach, Wolfgang Janni, Robert Landthaler, Andreas Kohls, Daniela Rezek, Thomas Noesselt, Gunnar Fischer, Stephan Henschen, Thomas Praetz, Volker Heyl, Thorsten Kühn, Thomas Krauss, Christoph Thomssen, Andre Hohn, Hans Tesch, Christoph Mundhenke, Alexander Hein, Claudia Rauh, Christian M. Bayer, Katja Schmidt, Erik Belleville, Sara Y. Brucker, Peyman Hadji, Matthias W. Beckmann, Diethelm Wallwiener, Sherko Kümmel, Andreas Hartkopf, Peter A. Fasching
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background Treatment of postmenopausal, hormone receptor-positive metastatic breast cancer (MBC) patients varies despite clear therapy guidelines, favoring endocrine treatment (ET). Aim of this study was to analyze persistence of palliative
Externí odkaz:
https://doaj.org/article/288dc4797ece43779ee02ebaad868ad3
Publikováno v:
Journal of Bone Oncology, Vol 22, Iss , Pp 100292- (2020)
Due to a significant increase in the overall survival of women with breast cancer (BC), preventing the long-term consequences of BC treatments is of the utmost importance. Treatments such as aromatase inhibitors (AI), chemotherapy (CHT), and tamoxife
Externí odkaz:
https://doaj.org/article/11342bfb37554c4fa4298b5d48d3cea5
Publikováno v:
Journal of Bone Oncology, Vol 18, Iss , Pp - (2019)
In recent years, cancer treatment-induced bone loss (CTIBL) and increased risk of fracture has become an emerging problem as breast cancer (BC) survival has increased due to early diagnosis and improved treatments. In premenopausal women with BC, che
Externí odkaz:
https://doaj.org/article/4e14725e6a2943c79fdc1464e8e89863
Autor:
Andreas Schneeweiss, Johannes Ettl, Diana Lüftner, Matthias W. Beckmann, Erik Belleville, Peter A. Fasching, Tanja N. Fehm, Matthias Geberth, Lothar Häberle, Peyman Hadji, Andreas D. Hartkopf, Carsten Hielscher, Jens Huober, Eugen Ruckhäberle, Wolfgang Janni, Hans Christian Kolberg, Christian M. Kurbacher, Evelyn Klein, Michael P. Lux, Volkmar Müller, Naiba Nabieva, Friedrich Overkamp, Hans Tesch, Elena Laakmann, Florin-Andrei Taran, Julia Seitz, Christoph Thomssen, Michael Untch, Pauline Wimberger, Rachel Wuerstlein, Bernhard Volz, Diethelm Wallwiener, Markus Wallwiener, Sara Y. Brucker
Publikováno v:
Breast, Vol 55, Iss , Pp 138-139 (2021)
Externí odkaz:
https://doaj.org/article/3ce18d162da74f4b92ea7082883a3131
Autor:
Andrew J. Browne, Marie L. Kubasch, Andy Göbel, Peyman Hadji, David Chen, Martina Rauner, Friedrich Stölzel, Lorenz C. Hofbauer, Tilman D. Rachner
Publikováno v:
Breast Cancer Research, Vol 19, Iss 1, Pp 1-15 (2017)
Abstract Background The mammalian target of rapamycin inhibitor everolimus is approved as an antitumor agent in advanced estrogen receptor-positive breast cancer. Surrogate bone marker data from clinical trials suggest effects on bone metabolism, but
Externí odkaz:
https://doaj.org/article/444b18b9589b483c89b20d8fb31ffd36
Autor:
Peyman Hadji, Matti S. Aapro, Jean-Jacques Body, Michael Gnant, Maria Luisa Brandi, Jean Yves Reginster, M. Carola Zillikens, Claus-C. Glüer, Tobie de Villiers, Rod Baber, G. David Roodman, Cyrus Cooper, Bente Langdahl, Santiago Palacios, John Kanis, Nasser Al-Daghri, Xavier Nogues, Erik Fink Eriksen, Andreas Kurth, Rene Rizzoli, Robert E. Coleman
Publikováno v:
Journal of Bone Oncology, Vol 7, Iss C, Pp 1-12 (2017)
Background: Several guidelines have been reported for bone-directed treatment in women with early breast cancer (EBC) for averting fractures, particularly during aromatase inhibitor (AI) therapy. Recently, a number of studies on additional fracture r
Externí odkaz:
https://doaj.org/article/dd613e2d1ba041a0b37c9b91088411bd
Autor:
Jonathan D. Adachi, Henry G. Bone, Nadia S. Daizadeh, Paula Dakin, Socrates Papapoulos, Peyman Hadji, Chris Recknor, Michael A. Bolognese, Andrea Wang, Celia J. F. Lin, Rachel B. Wagman, Serge Ferrari
Publikováno v:
BMC Musculoskeletal Disorders, Vol 18, Iss 1, Pp 1-8 (2017)
Abstract Background Denosumab treatment for up to 8 years in the FREEDOM study and Extension was associated with low fracture incidence. It was not clear whether subjects who discontinued during the study conduct had a higher risk of fracture than th
Externí odkaz:
https://doaj.org/article/82d84359d66240d5b137491968ed5b27